Sylvain E Lesné

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2112879/publications.pdf

Version: 2024-02-01

41 papers

6,974 citations

32 h-index 355658 38 g-index

46 all docs

46 docs citations

46 times ranked

9489 citing authors

#	Article	IF	CITATIONS
1	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chemical Reviews, 2021, 121, 2545-2647.	23.0	406
2	Soluble endogenous oligomeric \hat{l}_{\pm} -synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk. Journal of Parkinson's Disease, 2020, 10, 1-28.	1.5	40
3	Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of $\hat{l}\pm$ -synucleinopathy. Acta Neuropathologica, 2019, 138, 551-574.	3.9	58
4	Discrete Pools of Oligomeric Amyloid- \hat{l}^2 Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. American Journal of Pathology, 2018, 188, 739-756.	1.9	16
5	Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons. Acta Neuropathologica, 2018, 136, 589-605.	3.9	29
6	The amyloid- \hat{l}^2 oligomer A \hat{l}^2*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. Science Signaling, 2017, 10, .	1.6	90
7	Selective lowering of synapsins induced by oligomeric $\hat{l}\pm$ -synuclein exacerbates memory deficits. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4648-E4657.	3.3	45
8	Specific alterations of tau phosphorylation and neuronal signaling induced by the amyloid- \hat{l}^2 oligomer A \hat{l}^2 *56. Neurobiology of Aging, 2016, 39, S27.	1.5	0
9	Soluble Conformers of $\hat{Al^2}$ and Tau Alter Selective Proteins Governing Axonal Transport. Journal of Neuroscience, 2016, 36, 9647-9658.	1.7	47
10	Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease. Science Signaling, 2016, 9, ra47.	1.6	84
11	P2-055: Cellular prion protein and class-specific $\hat{Al^2}$ oligomers mediate plaque-associated cytopathology in a mouse model of Alzheimer's disease. , 2015, 11, P504-P504.		1
12	Genetic Modulation of Soluble AÂ Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2014, 34, 7871-7885.	1.7	74
13	Toxic oligomer species of amyloid- \hat{l}^2 in Alzheimer's disease, a timing issue. Swiss Medical Weekly, 2014, 144, w14021.	0.8	27
14	Brain amyloid-β oligomers in ageing and Alzheimer's disease. Brain, 2013, 136, 1383-1398.	3.7	384
15	Genetic modulation of soluble $\hat{Al^2}$ rescues cognitive and synaptic impairment in a mouse model of AD. Molecular Neurodegeneration, 2013, 8, .	4.4	O
16	Breaking the Code of Amyloid- <mml:math id="M1" xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi mathvariant="bold-italic">\hat{l}^2</mml:mi></mml:mrow></mml:math> Oligomers. International Journal of Cell Biology, 2013, 2013, 1-6.	1.0	25
17	Soluble Â-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology. Journal of Neuroscience, 2012, 32, 10253-10266.	1.7	107
18	The Complex PrP ^c -Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 16857-16871.	1.7	254

#	Article	IF	CITATIONS
19	Soluble AÎ ² oligomer production and toxicity. Journal of Neurochemistry, 2012, 120, 125-139.	2.1	312
20	Cognitive effects of cell-derived and synthetically derived $\hat{Al^2}$ oligomers. Neurobiology of Aging, 2011, 32, 1784-1794.	1.5	124
21	Detecting AÎ ² *56 Oligomers in Brain Tissues. Methods in Molecular Biology, 2010, 670, 45-56.	0.4	35
22	Plaque-bearing mice with reduced levels of oligomeric amyloid- \hat{l}^2 assemblies have intact memory function. Neuroscience, 2008, 151, 745-749.	1.1	163
23	Oligomers of the amyloid- \hat{l}^2 protein disrupt working memory: Confirmation with two behavioral procedures. Behavioural Brain Research, 2008, 193, 230-234.	1.2	75
24	Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticity. Brain, 2008, 131, 651-664.	3.7	208
25	Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models*. Journal of Biological Chemistry, 2007, 282, 23818-23828.	1.6	375
26	Involvement of -site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8167-8172.	3.3	107
27	\hat{l}^2 -Amyloid Modulation of Synaptic Transmission and Plasticity. Journal of Neuroscience, 2007, 27, 11832-11837.	1.7	107
28	A specific amyloid-l ² protein assembly in the brain impairs memory. Nature, 2006, 440, 352-357.	13.7	2,662
29	Orally available compound prevents deficits in memory caused by the Alzheimer amyloid- \hat{l}^2 oligomers. Annals of Neurology, 2006, 60, 668-676.	2.8	167
30	NMDA Receptor Activation Inhibits Â-Secretase and Promotes Neuronal Amyloid-Â Production. Journal of Neuroscience, 2005, 25, 9367-9377.	1.7	178
31	Akt-dependent Expression of NAIP-1 Protects Neurons against Amyloid-β Toxicity. Journal of Biological Chemistry, 2005, 280, 24941-24947.	1.6	51
32	Amyloid Plaques and Amyloid-Â Oligomers: An Ongoing Debate. Journal of Neuroscience, 2005, 25, 9319-9320.	1.7	23
33	Reduced brain tissue perfusion in TGF- \hat{l}^21 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities. Neurobiology of Disease, 2005, 19, 38-46.	2.1	47
34	Sp1 and Smad transcription factors co-operate to mediate TGF- \hat{l}^2 -dependent activation of amyloid- \hat{l}^2 precursor protein gene transcription. Biochemical Journal, 2004, 383, 393-399.	1.7	73
35	Transforming growth factor-beta and ischemic brain injury. Cellular and Molecular Neurobiology, 2003, 23, 539-550.	1.7	90
36	Transforming growth factor αâ€induced expression of typeâ€1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity. FASEB Journal, 2003, 17, 277-279.	0.2	48

SYLVAIN E LESNé

#	Article	IF	CITATIONS
37	Transforming Growth Factor- \hat{l}^21 Potentiates Amyloid- \hat{l}^2 Generation in Astrocytes and in Transgenic Mice. Journal of Biological Chemistry, 2003, 278, 18408-18418.	1.6	127
38	Smad3-Dependent Induction of Plasminogen Activator Inhibitor-1 in Astrocytes Mediates Neuroprotective Activity of Transforming Growth Factor- \hat{I}^2 1 against NMDA-Induced Necrosis. Molecular and Cellular Neurosciences, 2002, 21, 634-644.	1.0	77
39	Transforming Growth Factor-β1—Modulated Cerebral Gene Expression. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1114-1123.	2.4	24
40	Increased Expression of Transforming Growth Factor- \hat{l}^2 after Cerebral Ischemia in the Baboon: An Endogenous Marker of Neuronal Stress?. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 820-827.	2.4	37
41	Ischemia-Induced Interleukin-6 as a Potential Endogenous Neuroprotective Cytokine against NMDA Receptor-Mediated Excitoxicity in the Brain. Journal of Cerebral Blood Flow and Metabolism, 2000, 20, 956-966.	2.4	176